---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084444"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:41:52.386123+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Rallybio agrees to reverse merger with Candid; Rallybio holders get ~3.65% of combined firm

## Summary
- Rallybio pre-merger holders expected to own ~3.65% of combined company; Candid holders ~57.55%; financing investors ~38.80% (based on $505.5M raise).
- Concurrent $505.5M private placement from accredited investors, shares convert to Rallybio common at closing.
- Post-merger CEO will be Ken Song, current Candid Chairman/President/CEO; current Rallybio executives to resign.
- Rallybio regained Nasdaq $1.00 bid compliance after 1-for-8 reverse stock split effective Feb 6, 2026.
- Rallybio stockholders must approve share issuance (>20%), reverse split, name change to 'Candid Therapeutics, Inc.'

## SEC filing metadata
- accession: 0001193125-26-084444
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/0001193125-26-084444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084444
- JSON: https://secwatch.observer/filing/0001193125-26-084444.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084444.txt

## Key facts
- Material Agreements
  Rallybio Corp entered into Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. (effective 2026-03-01).
  - Action: entry
  - Agreement: merger
  - Counterparty: Candid Therapeutics, Inc.
  - Effective: 2026-03-01
  source text: On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/0001193125-26-084444-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.